Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...

Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...

Takeda Pharmaceutical Co. announced that its oral psoriasis drug zasocitinib proved safe and effective in late-stage trials, marking a milestone in its effort to treat the incurable skin condition and ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...